$NTHIAug 13, 2026, 2:31 PM ETAI processed

NTHI: Intranasal NEO100 Phase 2a posts strong PFS; patent portfolio hints at nose‐to‐brain platform

AI Summary

NeOnc (NTHI) reported Phase 2a intranasal NEO100 data in recurrent IDH1‐mutant high‐grade glioma: a 24‐patient, open‐label study produced 48.9% six‐month progression‐free survival versus a 20% historical benchmark (p=0.0047) and median overall survival of 26.09 months. The company also controls a sizable USC‐origin patent portfolio covering intranasal delivery and related compounds (NEO100/NEO212), which could turn the nose‐to‐brain approach into a broader CNS delivery platform — but the dataset is small and non‐randomized, and a registrational trial with FDA alignment is required to validate the technology and commercial potential.

Positives

Phase 2a (n=24) showed 48.9% six‑month PFS vs 20% historical benchmark (p=0.0047)
Median overall survival reported at 26.09 months with favorable short‑term survival rates
Large USC‑licensed patent portfolio (issued and pending US/international patents) covering intranasal delivery and related compounds; NEO212 has an identified Phase 2 dose

Negatives

Study was small (24 patients), open‑label and non‑randomized, limiting generalizability
Efficacy signal does not prove the intranasal delivery mechanism caused benefit; registrational proof is needed
Regulatory, patent/licensing, development cost and financing risks remain before commercial realization

Company Info

Company:: NeOnc Technologies Holdings Inc
Exchange:: Nasdaq
Industry:: Pharmaceuticals
Country:: US
Website:: https://neonc.com
Market cap:: 77.77M
Shares outstanding:: 25.93M

Now available

TradersLink Beta App

Free beta access for all TradersLink Discord members(free and premium members)

Session Tracker

Enter the executions you took each day and TradersLink builds the trades for you. Review them by ticker with trade replay charts, then add trade notes, tags, and rules. Finish the day with what went well, what to work on, and your main focus for next time.

Trade Analyzer

Analyze every trade—not just your totals. Review detailed entry, exit, and complete-trade analysis, then use long-term results to study your execution habits over time. See missed profit opportunities, exits that may have happened too early, and trades that were green before they finished red. Candle-pattern data helps you study the conditions around your entries and exits.

Smart Rules

Use preset trading rules that TradersLink can track from your recorded trades. Review when a rule may have been broken, see your results over time, and create custom rules for your own process.

Press Release Alerts

Get press-release alerts inside your dashboard, including alerts when a stock is halted, so important news is visible while you track your trades.

Trade Explorer

Open a completed trade and go deeper. Review its executions, result, notes, tags, rules, and analysis in one place.

Analytics

Understand your trading history from more than one angle. Explore results by ticker, time of day, holding time, setups, and other patterns supported by your recorded trades.

Log in for free
with your
discord accountLOG IN NOW!